Short-Term Investment Outlook – Netflix (NFLX)Recommendation: Neutral to Moderately Bullish (Short-Term)
Time Horizon: 1–4 weeks

Technical AnalysisNetflix has shown strong upward momentum in recent sessions, supported by consistent higher highs and higher lows. The stock is currently trading above key moving averages, indicating a short-term bullish trend.

• Support Levels: Recent consolidation zones may act as support on pullbacks.
• Resistance Levels: Near-term resistance is likely around recent swing highs; a breakout could trigger further upside momentum.
• Indicators: RSI is approaching overbought territory, suggesting a possible short-term pullback or consolidation before continuation.

Catalysts

• Continued positive sentiment around subscriber growth and content performance
• Broader strength in tech and growth stocks
• Any news related to earnings guidance or strategic partnerships

Risks

• Short-term overbought conditions increasing the likelihood of a pullback
• Market-wide volatility, especially in tech stocks
• Negative sentiment or unexpected news impacting streaming competition

Strategy

• Aggressive traders: Consider buying on minor pullbacks toward support levels
• Conservative traders: Wait for a confirmed breakout above resistance with volume
• Risk management: Tight stop-loss below recent support is recommended

ConclusionNetflix Inc. remains technically strong in the short term, but traders should be cautious of overextended conditions. A buy-on-dip strategy or breakout confirmation approach is advisable.

🟢 Guardian Pharmacy Services ($GRDN)
Rating: Strong Buy
Sector: Healthcare (Pharmacy Management)
Top Pick
Guardian Pharmacy Services delivered a standout performance on March 11, reporting an earnings per share (EPS) beat of +42%, significantly exceeding market expectations. Current AI-driven analysis indicates a high probability of continued upside momentum.
SST Score: 8/10 (Buy)
Ensemble Score: 14/15 (Very Bullish)
LSTM Score: 13/15 (Momentum Play)
Signal: Strong Buy
Price Target: $32.00
(Recently upgraded following earnings)
Strategic Outlook:
Organic growth within long-term care facilities is accelerating, reinforcing the company’s expansion trajectory. From a technical perspective, momentum remains exceptionally strong following last week’s confirmed breakout.
Earnings Date: March 11, 2026 🟢
(Reported – Strong Beat)

Why TERN Is a Top Swing Trade This Week Institutional Buying – The Boxer Capital EntryRecent 13F filings show that Boxer Capital Management initiated a new position of 375,000 shares (~$15 million).
Institutional accumulation ahead of an earnings event (March 19) is often interpreted as a strong bullish signal, suggesting large investors expect positive developments.

Analyst Optimism and Price Target UpgradesRecent weeks have seen significant upward revisions in analyst expectations.
Key highlights:

• Zacks Investment Research Rank #2 (Buy) – placing TERN in the top 20% of stocks based on earnings revisions.
  
• Average price target: $58.13
  
• Bullish outlier target: $73.50
  

Even while the broader healthcare sector shows mixed performance, TERN continues to display “Stage 2 momentum”, indicating a strong and sustained uptrend.

 Technical SetupPrice Action

• Friday close (March 13): $46.52
  
• +5% gain on the day
  

Support & Resistance

• 52-week high: $48.26
  
• A breakout above $48.30 could trigger a major technical breakout.
  

Volume

• 4.2 million shares traded on Friday
  
• Nearly double the average volume, suggesting active accumulation by institutional investors.
  

Trading Plan (TERN)Overall Rating: STRONG BUY
Terns Pharmaceuticals is currently one of the hottest biotech momentum plays, driven by the dual catalysts of the obesity drug market and CML treatment development.
Suggested StrategyEntry Options

• Buy breakout above $48.30 (new high)
  
• Or accumulate on a dip near $45.50
  

Price Target

• $58.00 short-term (analyst consensus)
  

Stop Loss

• $41.50 (below last week’s low)
  

Bottom Line:
TERN combines strong clinical catalysts, institutional accumulation, bullish analyst sentiment, and a near-term breakout setup. If momentum continues, the stock could push above $50 and potentially test the $58 analyst target in the coming weeks.

March 8, 2026
CorMedix Inc. (NASDAQ: CRMD) has emerged as one of the most actively discussed biotechnology stocks following the release of its quarterly earnings on March 5, 2026. While the company reported an earnings-per-share result that fell short of analyst expectations, investor sentiment remains constructive due to reaffirmed growth projections for its flagship product, DefenCath. The market’s reaction today reflects confidence in the company’s revenue trajectory and long-term commercialization strategy.
AI Scorecard OverviewSeveral AI-driven models provide a generally positive outlook for CorMedix, indicating a moderate probability of market outperformance in the near to medium term.

• SST-Score: 6/10 – Classified as Hold, with a projected +5.57% probability of outperforming the market.
• Ensemble Score: 11/15 – Strengthened by the company’s solid cash position of $148.5 million and the announcement of a $75 million share repurchase program.
• LSTM Score: 12/15 – Bullish signal suggesting price stabilization after the initial post-earnings reaction.
• SETUP-AI Score: 7/10 – Identifies a mean-reversion setup, indicating the stock may be oversold following the recent decline.
• Signal: 7/10 – Buy on dips, with investors focusing on the company’s guidance of $300M+ revenue for 2026.
• Sentiment-Score: 8/10 – Sentiment supported by analysts reaffirming price targets between $13 and $18.
• Fundamental-Score: 7/10 – Positive institutional ranking driven by operational profitability and positive EBITDA.

Total AI Score: 76 / 100 – BUY / ACCUMULATE
Earnings Reaction and Financial OutlookCorMedix reported EPS of $0.61, below the consensus estimate of $0.83. Despite the earnings miss, the company delivered strong revenue growth, reporting $128.6 million in revenue, a substantial increase compared to $22.4 million in the same period last year.
More importantly, management reaffirmed its 2026 guidance, projecting:

• Revenue: $300 – $320 million
• EBITDA: $100 – $125 million

This outlook reassures investors about the ongoing commercial scaling of DefenCath and the company’s improving profitability profile.
Strategic Developments and CatalystsTwo key developments are currently driving investor attention:
1. Share Repurchase Program
The company announced a $75 million stock buyback program, widely interpreted by quantitative models and analysts as a strong signal that management believes the current share price undervalues the company’s fundamentals.
2. Upcoming Clinical Catalyst
The next major catalyst is the Phase 3 data release for REZZAYO, expected in Q2 2026. This represents a significant binary event that could materially impact the company’s valuation and future growth prospects.
Trading PerspectiveFollowing the earnings reaction, AI-based models suggest that the recent pullback may present a tactical entry opportunity. The combination of improving revenue growth, strong liquidity, analyst support, and the newly announced buyback provides a supportive backdrop for a potential price recovery.
Suggested swing-trade framework:

• Entry Zone: $6.20 – $6.50
• Short-Term Target: $8.50
• Long-Term Potential: Analyst targets between $13 and $18
• Stop Loss: $5.80 (below recent support)

ConclusionDespite the short-term disappointment from the earnings-per-share miss, the broader investment thesis for CorMedix remains intact. Strong revenue growth, reaffirmed guidance, a substantial share repurchase program, and upcoming clinical catalysts support a constructive outlook. With an AI composite score of 76/100, the stock currently falls within the Buy / Accumulate range, suggesting that the recent dip may represent an attractive opportunity for investors positioning ahead of further operational milestones and clinical developments.